

Pathogens of the Respiratory System

Chapter 21, Pages 531 - 567

1. Respiratory System Introduction

A. Anatomy (Pages 532 - 534)

i. Upper Respiratory Track

a. Nasal Hairs

b. Paranasal Sinuses

c. Nasal Chonchae

d. Ciliated Pseudostratified Columnar Epithelia

e. Pharynx

f. Epiglottis

g. Tonsils

- Pharyngeal Tonsils (Adionoids)

- Palatine Tonsils

- Lingual Tonsils

h. Eustachian Tube and Inner ear

ii. Normal Flora of Upper Respiratory Tract

a. *Staphylococcus aureus*

2. *Streptococcus sp.* (Page 534)

A. General Information

B. Taxonomy (Pages 534 - 535)

i. Blood Agar

a. α -hemolytic (Viridans)

b. β -hemolytic

- Hemolysins

- Antigenic Carbohydrates (A-T) (Page 535)

c. γ -hemolytic

C. *Streptococcus pyogenes* “Group A β -hemolytic Streptococci”

i. Antigenic Protein - M protein (Page 535)

ii. Other Virulence Factors

a. DNase

b. Hyaluronidase

c. Streptokinase

d. Streptolysins O and S

e. Erythrogenic Toxin

f. Leukocidin

iii. Diseases of Group A β -hemolytic Streptococci

a. Pharyngitis (“Strep Throat”)

- Scarlet Fever (p. 683)
 - * Lysogenic Conversion
 - * Erythrogenic Toxin (Page 536)

- “Flesh Eating” *Streptococcus pyogenes*

- * Necrotizing Fasciitis
 - * “Super Antigens”


iv. Late Nonsuppurative Sequelae (Pages 537 - 538)

a. Rheumatic Fever

b. Glomerulonephritis

3. *Corynebacterium diphtheriae* (Pages 538 - 541)

A. Virulence Factors



B. Treatment

- i. Antisera
- ii. Tracheotomy
- iii. Antibiotics

C. Prevention by Vaccine

- i. Children - DTaP
 - b. Diphtheria Toxoid
- ii. Adult - Td

- D. *Streptococcus pneumoniae* (ages 541 - 543; 546 - 548)
 - i. General Information (Pages 546 - 547)
 - ii. Virulence Factors
 - a. Polysaccharide Capsule (Pages 546 - 547)
 - 90 Serotypes
 - C3b Compliment Interference (Page 547)
 - b. Hemolysin
 - c. Leukocidin
 - d. Hyaluronidase
 - iii. Diseases
 - Lobar pneumonia (Page 547)
 - Bacteremia (Page 547)
 - Meningitis (Page 547)
 - Otitis media (Page 542 - 543)
 - iv. Vaccines (Pages 547 - 548)
 - PPSV23 (Pneumococcal Polysaccharide Vaccine, 23 Serotypes)
 - PCV13 (Pneumococcal Conjugate Vaccine, 13 Serotypes)

4. *Streptococcus pneumoniae* (ages 541 - 543; 546 - 548)

i. General Information (Pages 546 - 547)

ii. Virulence Factors

a. Polysaccharide Capsule (Pages 546 - 547)

- 90 Serotypes
- C3b Compliment Interference (Page 547)

b. Hemolysin

c. Leukocidin

d. Hyaluronidase

iii. Diseases

a Lobar pneumonia (Page 547)

b Bacteremia (Page 547)

c Meningitis (Page 547)

d Otitis media (Page 542 - 543)

iv. Vaccines (Pages 547 - 548)

a. PPSV23 (Pneumococcal Polysaccharide Vaccine, 23 Serotypes)

b. PCV13 (Pneumococcal Conjugate Vaccine, 13 Serotypes)

5. *Haemophilus influenzae* (Hib) (Pages 541 - 543)

A. Virulence Factors

i. Capsule (type b)

B. Diseases

i. Meningitis

- Brain Damage

ii. Acute Epiglottitis

iii. Middle Ear Infections (Otitis Media)

iv. Hib Vaccine

- a. Conjugated Vaccine

6. *Klebsielle Pneumoniae* (Pages 548 - 549)

A. Transmission (Pages 548)

B. Virulence Factor

i. Capsule

- C3b Compliment Interference, probable

ii. Colonization Factors (Adhesins) (Page 548)

iii. Cytotoxic

iv. Resistance

- plasmid borne b-lactimase producers
- Extended spectrum b-lactimase producers effect also cephalosporins
- Carbapenem resistant - Carbapenems have b-lactam ring and used as a last resort.

7. *Mycoplasma pneumoniae* (Pages 549 - 550)

Note: “*Atypical Pneumonias* consist of
Mycoplasmas
Respiratory viruses
Chlamydias (psittacosis)
Rickettsiae (Q fever)
Legionella
Characteristics

A. Virulence Factors

- i. Crowded conditions
 - a. Aerosolized Droplets
- ii. Autoimmune Response

B. Diseases


- i. Mycoplasmal pneumonia (or Primary Atypical Pneumonia or “Walking Pneumonia”)

C. Drugs

8. *Bordetella pertussis* (Pages 550 - 551)

A. Virulence Factor

- i. Colonization Factors
- ii. Tracheal Cytotoxin
- iii. Pertussis toxin (A-B Exotoxin)



B. Disease - Whooping Cough (Pertussis)

i. Stages

a. Catarrhal Stage

b. Paroxysmal Stage

c. Convalescence Stage

ii. Vaccine

a. Whole Cell

b. Purified Cell Fraction (aP - Acellular Pertussis Vaccine)

iii. Contemporary State

a. DTaP Vaccine

b. Tdap Booster

9. *Mycobacterium tuberculosis* (Pages 551 - 556)

- A. Historical Perspective
- B. Transmission
- C. Latent Tuberculosis Infection (LTBI) (Page 552 ff)
- D. Tuberculosis Disease (Pages 553 - 554)
 - i. Primary Infection
 - ii. Caseation Necrosis
 - iii. Miliary Tuberculosis
 - Tuberculous Meningitis - etc etc etc
- E. Chemotherapy
 - i. First line - 8 weeks

Isoniazid (INH)	Rifampin
Pyrazinamide	Ethambutol
Then - 18 weeks	
Isoniazid (INH)	Rifampin
 - ii. Second line

Aminosalicylic acid & salts	Capromycin
Cycloserine	Ethionamide
Streptomycin	

F. Diagnosis

- i. Tuberculin Skin Test (Mantoux test)
- ii. Blood tests
- iii. x ray

G. Vaccine

- i. *Mycobacterium bovis*

H. AIDS Patients

I. Epidemic

10. *Legionella pneumophila* (Pages 556 - 557)

A. Historical Perspective

B. Overview

C. Diseases

- i. Legionnaires' Disease